FLT3 and acute myeloid leukemia: Detailed docking, DFT calculations and 20-ns MD simulation of the new hits in the DFG-in FLT3-modeled structure revealed that BPR056 (Ml wt: 325.32; cLogP: 2.48) formed a stable interaction with the target and that it may be a suitable lead for AML treatment.